Altimmune to Report Q1 2026 Financial Results on May 13
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy ALT?
Source: Newsfilter
- Earnings Announcement: Altimmune is set to report its Q1 2026 financial results on May 13, 2026, with management hosting a conference call at 8:30 a.m. ET to discuss the results and provide a business update, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The call will be webcast live on Altimmune's Investor Relations website, and participants must register in advance to receive dial-in numbers and a unique PIN, ensuring investors can easily access the latest information.
- Key Drug Candidate: Altimmune's lead candidate, pemvidutide, is a unique dual-action therapy targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD), showcasing the company's innovative potential in liver disease treatment.
- Company Overview: As a late clinical-stage biopharmaceutical company, Altimmune focuses on developing therapies for serious liver diseases, indicating its strategic positioning and responsiveness to market demand in the biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALT
Wall Street analysts forecast ALT stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.040
Low
12.00
Averages
16.00
High
20.00
Current: 3.040
Low
12.00
Averages
16.00
High
20.00
About ALT
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed Phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altimmune to Report Q1 2026 Financial Results on May 13
- Earnings Announcement: Altimmune is set to report its Q1 2026 financial results on May 13, 2026, with management hosting a conference call at 8:30 a.m. ET to discuss the results and provide a business update, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The call will be webcast live on Altimmune's Investor Relations website, and participants must register in advance to receive dial-in numbers and a unique PIN, ensuring investors can easily access the latest information.
- Key Drug Candidate: Altimmune's lead candidate, pemvidutide, is a unique dual-action therapy targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD), showcasing the company's innovative potential in liver disease treatment.
- Company Overview: As a late clinical-stage biopharmaceutical company, Altimmune focuses on developing therapies for serious liver diseases, indicating its strategic positioning and responsiveness to market demand in the biopharmaceutical industry.
See More
Analyst Reiterates Strong Buy Rating for VKTX Ahead of Earnings
- Strong Buy Rating: Raymond James reiterated a 'Strong Buy' rating on Viking Therapeutics (VKTX) with a $118 price target, implying a substantial 258% upside, reflecting analysts' strong confidence in the company's future performance.
- Financial Expectations: Consensus estimates anticipate VKTX will report a GAAP loss per share of $1.03, widening from last year's $0.4 loss, with projected EBITDA losses nearing $129.5 million, indicating ongoing financial pressures as the company remains in the clinical stage.
- Clinical Trial Progress: Investor focus remains on the ongoing Phase 3 Vanquish obesity treatment program, with enrollment for the second phase completed in March and results from a maintenance-dose study expected in Q3, highlighting strong demand for new treatment options.
- Intensifying Market Competition: As emerging biotech firms and large pharma companies expand their obesity drug pipelines, competition is intensifying, with Viking facing challenges from companies like Structure Therapeutics and Altimmune, while Eli Lilly's new drug Foundayo shows slower initial prescription data.
See More
Lululemon's New CEO Announcement Triggers Stock Decline
- Leadership Transition Impact: Lululemon's announcement of a new CEO taking over in September led to a 13% drop in stock price, as investors expressed concerns over the uncertainty during the transition period, particularly with signs of weakness in North American sales prompting many shareholders to exit to mitigate risk.
- Lucid's Financial Health Concerns: Despite securing new funding and appointing a new CEO, Lucid's stock fell over 9% as investor worries about ongoing losses and high production costs overshadowed optimism, with Uber's increased stake failing to alleviate market concerns regarding its financial stability.
- Altimmune's Dilution Fears: Altimmune's announcement of a $225 million stock offering to fund its MASH clinical trial resulted in a 16% decline in stock price, as market fears of dilution intensified, even though the company plans to direct the proceeds toward its upcoming Phase 3 study.
- Retail Investor Sentiment: On social media, investors expressed disappointment in Lululemon's management capabilities, suggesting the company should consider a sale, while some Lucid investors believe the current stock price undervalues its assets, indicating market expectations for a potential rebound.
See More
Altimmune Prices $225 Million Public Offering at 13.5% Discount
- Offering Overview: Altimmune has announced a public offering of approximately 64.3 million shares at $3 per share, along with warrants, raising a total of $225 million at a 13.5% discount, negatively impacting investor sentiment as shares fell about 13% in pre-market trading.
- Funding for Clinical Trials: The proceeds from this offering will support the Phase 3 trial of Pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), which is expected to test multiple doses over 52 weeks, potentially accelerating drug approval through liver biopsy-based endpoints.
- FDA Breakthrough Therapy Designation: Pemvidutide received Breakthrough Therapy Designation from the FDA in January, aimed at expediting the development and review of treatments showing significant improvement over existing options, indicating strong market potential for the drug.
- Investor Sentiment Shift: Following the public offering announcement, retail sentiment on Stocktwits shifted from 'bullish' to 'neutral', with message volumes increasing by 182% in 24 hours, reflecting market concerns about the company's future and expectations of dilution.
See More
Altimmune Prices Oversubscribed $225 Million Public Offering
- Fundraising Scale: Altimmune's priced public offering is expected to raise approximately $225 million in gross proceeds, comprising 64.25 million shares of common stock and 10.75 million pre-funded warrants, indicating strong market demand for its shares.
- Warrant Details: Each pre-funded warrant has a nominal exercise price of $0.001, while the common stock warrants have an exercise price of $3.00 per share, with a combined offering price of $2.999, providing investors with a lower entry point.
- Use of Proceeds: The net proceeds from this offering will fund the upcoming Phase 3 trial in MASH, as well as working capital and general corporate purposes, highlighting the company's commitment to future research and development.
- Market Reaction: Although Altimmune's stock closed up 1.76% at $3.47 on Wednesday, it plunged 12.39% to $3.04 in the overnight market, reflecting investor caution regarding the company's outlook.
See More
Altimmune Prices Oversubscribed Public Offering Raising $225 Million
- Funding Size: Altimmune successfully priced an oversubscribed public offering expected to raise approximately $225 million in gross proceeds, reflecting strong market demand for its stock and enhancing the company's financial capacity to support future R&D.
- Offering Details: The offering includes 64.25 million shares of common stock and pre-funded warrants to purchase up to 10.75 million shares of common stock, with each security accompanied by common stock warrants at an exercise price of $3.00 per share, providing investors with additional potential upside.
- Underwriter Role: Leerink Partners and Barclays acted as joint bookrunning managers for the offering, indicating confidence from these financial institutions in Altimmune and potentially paving the way for the company's future capital market activities.
- Market Reaction: Despite cautious sentiment regarding Altimmune's prospects, the successful financing demonstrates investor confidence in its potential products, particularly in the context of the company's plans for late-stage clinical trials.
See More
Altimmune to Report Q1 2026 Financial Results on May 13
- Earnings Announcement: Altimmune is set to report its Q1 2026 financial results on May 13, 2026, with management hosting a conference call at 8:30 a.m. ET to discuss the results and provide a business update, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The call will be webcast live on Altimmune's Investor Relations website, and participants must register in advance to receive dial-in numbers and a unique PIN, ensuring investors can easily access the latest information.
- Key Drug Candidate: Altimmune's lead candidate, pemvidutide, is a unique dual-action therapy targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD), showcasing the company's innovative potential in liver disease treatment.
- Company Overview: As a late clinical-stage biopharmaceutical company, Altimmune focuses on developing therapies for serious liver diseases, indicating its strategic positioning and responsiveness to market demand in the biopharmaceutical industry.
See More
Analyst Reiterates Strong Buy Rating for VKTX Ahead of Earnings
- Strong Buy Rating: Raymond James reiterated a 'Strong Buy' rating on Viking Therapeutics (VKTX) with a $118 price target, implying a substantial 258% upside, reflecting analysts' strong confidence in the company's future performance.
- Financial Expectations: Consensus estimates anticipate VKTX will report a GAAP loss per share of $1.03, widening from last year's $0.4 loss, with projected EBITDA losses nearing $129.5 million, indicating ongoing financial pressures as the company remains in the clinical stage.
- Clinical Trial Progress: Investor focus remains on the ongoing Phase 3 Vanquish obesity treatment program, with enrollment for the second phase completed in March and results from a maintenance-dose study expected in Q3, highlighting strong demand for new treatment options.
- Intensifying Market Competition: As emerging biotech firms and large pharma companies expand their obesity drug pipelines, competition is intensifying, with Viking facing challenges from companies like Structure Therapeutics and Altimmune, while Eli Lilly's new drug Foundayo shows slower initial prescription data.
See More
Lululemon's New CEO Announcement Triggers Stock Decline
- Leadership Transition Impact: Lululemon's announcement of a new CEO taking over in September led to a 13% drop in stock price, as investors expressed concerns over the uncertainty during the transition period, particularly with signs of weakness in North American sales prompting many shareholders to exit to mitigate risk.
- Lucid's Financial Health Concerns: Despite securing new funding and appointing a new CEO, Lucid's stock fell over 9% as investor worries about ongoing losses and high production costs overshadowed optimism, with Uber's increased stake failing to alleviate market concerns regarding its financial stability.
- Altimmune's Dilution Fears: Altimmune's announcement of a $225 million stock offering to fund its MASH clinical trial resulted in a 16% decline in stock price, as market fears of dilution intensified, even though the company plans to direct the proceeds toward its upcoming Phase 3 study.
- Retail Investor Sentiment: On social media, investors expressed disappointment in Lululemon's management capabilities, suggesting the company should consider a sale, while some Lucid investors believe the current stock price undervalues its assets, indicating market expectations for a potential rebound.
See More
Altimmune Prices $225 Million Public Offering at 13.5% Discount
- Offering Overview: Altimmune has announced a public offering of approximately 64.3 million shares at $3 per share, along with warrants, raising a total of $225 million at a 13.5% discount, negatively impacting investor sentiment as shares fell about 13% in pre-market trading.
- Funding for Clinical Trials: The proceeds from this offering will support the Phase 3 trial of Pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), which is expected to test multiple doses over 52 weeks, potentially accelerating drug approval through liver biopsy-based endpoints.
- FDA Breakthrough Therapy Designation: Pemvidutide received Breakthrough Therapy Designation from the FDA in January, aimed at expediting the development and review of treatments showing significant improvement over existing options, indicating strong market potential for the drug.
- Investor Sentiment Shift: Following the public offering announcement, retail sentiment on Stocktwits shifted from 'bullish' to 'neutral', with message volumes increasing by 182% in 24 hours, reflecting market concerns about the company's future and expectations of dilution.
See More
Altimmune Prices Oversubscribed $225 Million Public Offering
- Fundraising Scale: Altimmune's priced public offering is expected to raise approximately $225 million in gross proceeds, comprising 64.25 million shares of common stock and 10.75 million pre-funded warrants, indicating strong market demand for its shares.
- Warrant Details: Each pre-funded warrant has a nominal exercise price of $0.001, while the common stock warrants have an exercise price of $3.00 per share, with a combined offering price of $2.999, providing investors with a lower entry point.
- Use of Proceeds: The net proceeds from this offering will fund the upcoming Phase 3 trial in MASH, as well as working capital and general corporate purposes, highlighting the company's commitment to future research and development.
- Market Reaction: Although Altimmune's stock closed up 1.76% at $3.47 on Wednesday, it plunged 12.39% to $3.04 in the overnight market, reflecting investor caution regarding the company's outlook.
See More
Altimmune Prices Oversubscribed Public Offering Raising $225 Million
- Funding Size: Altimmune successfully priced an oversubscribed public offering expected to raise approximately $225 million in gross proceeds, reflecting strong market demand for its stock and enhancing the company's financial capacity to support future R&D.
- Offering Details: The offering includes 64.25 million shares of common stock and pre-funded warrants to purchase up to 10.75 million shares of common stock, with each security accompanied by common stock warrants at an exercise price of $3.00 per share, providing investors with additional potential upside.
- Underwriter Role: Leerink Partners and Barclays acted as joint bookrunning managers for the offering, indicating confidence from these financial institutions in Altimmune and potentially paving the way for the company's future capital market activities.
- Market Reaction: Despite cautious sentiment regarding Altimmune's prospects, the successful financing demonstrates investor confidence in its potential products, particularly in the context of the company's plans for late-stage clinical trials.
See More
